Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: NORVIR

« Back to Dashboard

Norvir is a drug marketed by Abbott and Abbvie and is included in four NDAs. It is available from one supplier. There are seventeen patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in NORVIR is ritonavir. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. There is one tentative approval for this compound. Additional details are available on the ritonavir profile page.

Summary for Tradename: NORVIR

Patents:17
Applicants:2
NDAs:4
Suppliers: see list1

Clinical Trials for: NORVIR

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin
Status: Completed Condition: HIV Infections; Hyperlipidemia

PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)
Status: Active, not recruiting Condition: HIV Infections

Bioequivalence Study of Generic GPO Ritonavir Versus Norvir®
Status: Completed Condition: Healthy

Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study
Status: Active, not recruiting Condition: HIV Infections

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
Status: Completed Condition: Human Immunodeficiency Virus Type 1 (HIV-1); HIV Infections

Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects
Status: Completed Condition: HIV Infections

Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
Status: Completed Condition: Acquired Immunodeficiency Syndrome

Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole
Status: Completed Condition: Pharmacokinetics of Isavuconazole; Pharmacokinetics of Lopinavir/Ritonavir; Healthy Volunteers

A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants
Status: Completed Condition: Healthy

Bioequivalence Study of Generic GPO Saquinavir and Norvir® Versus Invirase® and Norvir®
Status: Withdrawn Condition: HIV Infections

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
NORVIR
ritonavir
TABLET;ORAL022417Feb 10, 2010RXYes5,635,523*PED<disabled>Y<disabled>
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945Jun 29, 1999RXYes6,037,157*PED<disabled>Y<disabled>
Abbvie
NORVIR
ritonavir
SOLUTION;ORAL020659Mar 1, 1996RXYes5,635,523*PED<disabled>Y<disabled>
Abbvie
NORVIR
ritonavir
TABLET;ORAL022417Feb 10, 2010RXYes8,470,347*PED<disabled>Y<disabled>
Abbvie
NORVIR
ritonavir
SOLUTION;ORAL020659Mar 1, 1996RXYes6,703,403*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: NORVIR

Drugname Dosage Strength RLD Submissiondate
ritonavirCapsules100 mgNorvir10/31/2012
ritonavirTablets100 mgNorvir12/21/2010
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc